IRCT20230607058409N1招募中1 期
Comparison of the effect of empagliflozin and metformin with Melijent and metformin in chronic kidney failure patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 75 years（—）
- 性别
- All
入选标准
- •Patients with over 20mL/min/1.73m2 (calculated by MDRD formula) in the first visit
- •Patient over 18 years old patients
- •-Patients with less 60 ml /min/1.73m2 (calculated by MDRD formula) in the first visit
排除标准
- •Class four congestive heart failure
- •Recurrent urinary infection
- •Myocardial infarction, stroke, transient ischemic attack
研究者
相似试验
招募中
Unknown
Bioequivalence Study of Empagliflozin/Metformin 5/500 mgThis study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N95Kharazmi Pharmacy24
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
尚未招募
3 期
Comparison of therapeutic effect of Empagliflozin (Gloripa) and Sitagliptin (Ziptin) on type 2 Diabetic patientsIRCT20200810048355N1Vice Chancellor for Research, Islamic Aazad University, Najafabad branch128
招募中
3 期
Comparing the effectiveness of Empagliflozin with Metformin in controlling Diabetes Mellitus in patients with post-organ transplant diabetesIRCT20230315057726N1Islamic Azad University40
招募中
2 期
The cardiac effect of pioglitazone and empagliflozin among diabetic patients with NAFLDCondition 1: Nonalcoholic fatty liver disease. Condition 2: Type 2 Diabetes. Condition 3: Cardiomyopathy.Nonalcoholic steatohepatitis (NASH)Type 2 diabetesK75.81CardiomyopathyIRCT20190122042450N5Iran University of Medical Sciences70